Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Allergy Therapeutics unveils new non-executive director

Jean-Yves Pavee retired from the board last night and has been replaced by Jeff Barton, who has been nominated by Abbott Laboratories.
Board room seats
Barton has served Abbott since joining in 1990

Allergic disorders specialist Allergy Therapeutics plc (LON:AGY) has announced a change of non-executive directors on the board.

Jean-Yves Pavee retired from the board last night and has been replaced by Jeff Barton, who has been nominated by Abbott Laboratories.

Barton currently serves as vice president of licensing and acquisitions at Abbott.

During his time in this role, Abbott has executed several strategically important transactions including the acquisition of St. Jude Medical, CFR Pharmaceuticals and Veropharm. 

“He brings extensive commercial experience, particularly in the United States, which will be valuable to our company as we continue to execute our global strategy. We also wish to take this opportunity to thank Jean-Yves for his contribution and support to Allergy Therapeutics since 2014," said Peter Jensen, chairman of Allergy Therapeutics.

View full AGY profile View Profile

Allergy Therapeutics plc Timeline

Related Articles

test tubes
January 22 2018
Under former chief executive Peter George and his successor Shaun Chilton, it has been transformed via a series of well-judged, quickly integrated and, crucially, cash generative acquisitions
leg bones
March 31 2018
"We are now in the position of really trying to kick on in 2018"
blood
April 01 2018
The company is in the process of raising £5mln, with a possible further £1mln through a share issue at 52.5p

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use